Astellas has ended work on a cell therapy that it was exploring for CD20-positive B cell lymphomas, the Japan-based pharma ...
Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...
As we start the New Year, it’s time to schedule your annual wellness visit. This important appointment is to talk about any ...
In recent years, the FDA has amped up its supervision of accelerated approvals, including by requiring that confirmatory ...
Brookline raised the firm’s price target on Caribou Biosciences (CRBU) to $34 from $26 and keeps a Buy rating on the shares. Caribou plans to ...
A recent retrospective study has shed new light on the effectiveness of chimeric antigen receptor T cell therapy for patients ...
The ASX dipped a tad on Friday, while uranium miners rose after Cameco halted production. Also… news just in – Trudeau looks set to quit.
ASX rides Wall Street’s bounce, energy stocks soar, Insignia jumps on takeover bid and Bellevue Gold takes a dive.
Knight Therapeutics Inc. (TSE:GUD – Get Free Report)’s stock price was up 0.6% during mid-day trading on Friday . The company traded as high as C$5.41 and last traded at C$5.37. Approximately 22,259 ...
Oreofe Odejide had always wanted to be a doctor after spending much time growing up accompanying her father on his rounds as an obstetrician–gynaecologist in Ile-Ife, Nigeria. And with her mum a ...
T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...